Sodium picosulfate is a contact stimulant laxative used as a treatment for constipation or to prepare the large bowel before colonoscopy or surgery. It is available as a generic medication. Chemically it is an oral prodrug that is converted by colonic bacterial enzymatic hydrolysis to active cathartic metabolites that increase colonic peristalsis and decrease water absorption in the large intestine. Typical physical properties for the active pharmaceutical ingredient are a white to off-white crystalline powder with good stability under recommended storage conditions, low systemic absorption after oral administration, and predominant faecal elimination of active metabolites. Formulations include oral solution, sachet for reconstitution and tablet presentations; onset of action for oral preparations is generally within 6 to 12 hours depending on dose and formulation. Standard analytical control uses HPLC for potency and impurity profiling, validated dissolution and microbial limits for oral dosage forms, and packaging designed to protect from moisture.
Parent: Sodium Picosulfate Monohydrate/ Sodium Picosulfate
Parent: Sodium Picosulfate
Typical quality specifications for sodium picosulfate API and finished products include assay by HPLC at not less than 98.5% and not more than 101.0% of the stated amount, individual related synthetic impurities limited to not more than 0.2% each, and total impurities not to exceed 1.0%. Known related compounds include low-level dealkylated and desulfonated derivatives and minor pyridine ring degradation products; each of these is typically limited to 0.5% or less when identified and quantified. Additional routine controls include loss on drying or water content typically not greater than 2.0%, residual solvents below ICH Q3C permissible daily exposure limits, elemental impurities within pharmacopeial limits (heavy metals commonly limited to 20 ppm or less), and specified microbial limits for nonsterile oral products.
Sodium picosulfate is used to relieve occasional constipation and to induce bowel evacuation prior to diagnostic procedures or surgery; it acts locally in the colon as a stimulant laxative and is supplied in oral formulations intended for short term use or single preprocedural dosing.
Daily long term use of stimulant laxatives including sodium picosulfate is not generally recommended without medical supervision because prolonged use can cause electrolyte disturbances, decreased bowel function dependence and masking of underlying conditions; for chronic constipation discuss alternatives and a management plan with a healthcare professional.
No, Dulcolax is a brand name that commonly refers to products containing bisacodyl in many markets; bisacodyl and sodium picosulfate are different chemical entities that both act as stimulant laxatives but have different structures, formulation profiles and dosing recommendations, so check the product label or consult a pharmacist to confirm the active ingredient.
